Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiogenXSWX:BIIB 69 Earnings Yield (Joel Greenblatt) % is 0.00% as of Jun. 2026. GuruFocus rates XSWX:BIIB with a GF Score™ of 69/100 and a GF Value™ of CHF162.42. The stock has 7 warning signs investors should review. Among 1,010 Drug Manufacturers companies, Biogen ranks better than 64.65% on this metric.
Biogen's Enterprise Value for the quarter that ended in Jun. 2026 was CHF31,564 Mil.
Biogen's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was CHF1,029 Mil. Biogen's Earnings Yield (Joel Greenblatt) for the quarter that ended in Jun. 2026 was 0.00%.
The historical rank and industry rank for Biogen's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
XSWX:BIIB'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 3.52 Med: 8.39 Max: 16.49
Current: 5.82
During the past 13 years, the highest Earnings Yield (Joel Greenblatt) of Biogen was 16.49%. The lowest was 3.52%. And the median was 8.39%.
XSWX:BIIB's Earnings Yield (Joel Greenblatt) % is ranked better than 64.65% of 1010
companies
in the Drug Manufacturers industry
Industry Median: 3.34
vs XSWX:BIIB: 5.82
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Biogen's Forward Rate of Return (Yacktman) % for the quarter that ended in Jun. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Biogen Earnings Yield (Joel Greenblatt) % Related Terms
Biogen Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Biogen's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - General subindustry, Biogen's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biogen Earnings Yield (Joel Greenblatt) % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biogen's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Biogen's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Biogens Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Biogen's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF1,029 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 0.00% mean?
Biogen (XSWX:BIIB) has a Earnings Yield (Joel Greenblatt) % of 0.00% as of Jun. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Biogen and its competitors. Over the past decade, Biogen's Earnings Yield (Joel Greenblatt) % has ranged from 3.52 to 16.49. According to the industry distribution chart, Biogen ranks #357 out of 1010 companies in the Drug Manufacturers industry, placing it in the top 35.3%.
Is Biogen's Earnings Yield (Joel Greenblatt) % too high?
Biogen's current Earnings Yield (Joel Greenblatt) % is 0.00%. Over the past 10 years, this metric has ranged from a low of 3.52 to a high of 16.49. Based on the distribution chart, Biogen ranks #357 out of 1010 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Biogen has a GF Score™ of 69/100, reflecting its overall financial health beyond just this single metric.
How does Biogen's Earnings Yield (Joel Greenblatt) % compare to OGN and AMRN?
According to the Drug Manufacturers industry distribution chart, Biogen ranks #357 out of 1010 companies for Earnings Yield (Joel Greenblatt) %. This puts Biogen in the upper half of its industry. The industry median Earnings Yield (Joel Greenblatt) % is 3.34. Historically, Biogen's own Earnings Yield (Joel Greenblatt) % has ranged from 3.52 to 16.49 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Drug Manufacturers company?
The median Earnings Yield (Joel Greenblatt) % among Drug Manufacturers companies is 3.34, based on 1,010 companies in the industry. Companies in the top quartile (top 25%) have a Earnings Yield (Joel Greenblatt) % significantly above this median, while those in the bottom quartile fall well below. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Biogen and its competitors. For the Drug Manufacturers industry, the median Earnings Yield (Joel Greenblatt) % is 3.34 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biogen's current Earnings Yield (Joel Greenblatt) % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biogen stock overvalued right now?
Biogen (XSWX:BIIB) has a current Earnings Yield (Joel Greenblatt) % of 0.00%. The stock's GF Value™ is CHF162.42, compared to a current price of CHF173.46 — trading 6.8% above its estimated fair value. The current Earnings Yield (Joel Greenblatt) % is 0.00%. Biogen's overall GF Score™ is 69/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Biogen (XSWX:BIIB), the current Earnings Yield (Joel Greenblatt) % is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biogen (XSWX:BIIB) Overvalued in 2026?
Based on GuruFocus' analysis, Biogen stock appears to be overvalued.
The current stock price of CHF173.46 is trading 6.8% above its estimated GF Value™ of CHF162.42.
Key valuation signals for XSWX:BIIB:
Earnings Yield (Joel Greenblatt) %: 0.00%
GF Value™: CHF162.42 vs. price of CHF173.46 (6.8% above fair value)
No single metric tells the full story. See the XSWX:BIIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
69GF Score
Get the complete analysis for XSWX:BIIB
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BIIB has been successfully added to your 
